5 Key Takeaways

• 1

  Europe's CDMO sector must embrace antifragility to thrive amid disruptions like inflation and geopolitical turbulence.

• 2

  CDMOs are essential for Europe's biopharma renaissance, providing infrastructure and expertise for biotech innovators.

• 3

  European CDMOs can leverage regulatory challenges as competitive advantages by demonstrating ESG compliance and digital transparency.

• 4

  Specialization in advanced therapies positions CDMOs as key players in modern pharma, enabling small biotechs to access complex modalities.

• 5

  To succeed, CDMOs should diversify supply chains, embrace digital production, and pursue strategic M&A for resilience.